Coronary disease & ACS

Computed Tomography Cardiac Angiography Before Invasive Coronary Angiography in Patients With Previous Bypass Surgery: The BYPASS-CTCA Trial

CirculationPublished Randomised controlled trial

Authors' conclusion

For patients with previous coronary artery bypass grafting, CTCA before ICA leads to reductions in procedure time and contrast-induced nephropathy, with improved patient satisfaction.

Study context

Population
Patients with previous CABG referred for invasive coronary angiography (ICA)
Participants
688 patients
Comparison
Computed tomography cardiac angiography (CTCA) before ICA vs ICA alone
Primary endpoint
Co-primary: ICA procedural duration, patient satisfaction after ICA (validated questionnaire), incidence of contrast-induced nephropathy
Methodological detailssingle-centre, open-label
  • Single-centre
  • Open-label

Primary result

As reported in the abstract

CTCA+ICA

Procedure duration (mean±SD)
18.6±9.5 minutes
Contrast-induced nephropathy
3.4%

ICA alone

Procedure duration (mean±SD)
39.5±16.9 minutes
Contrast-induced nephropathy
27.9%

Procedure duration (mean±SD)

CTCA+ICA18.6±9.5 minutes
ICA alone39.5±16.9 minutes

Contrast-induced nephropathy

CTCA+ICA3.4%
ICA alone27.9%
CTCA+ICA vs ICA aloneDifference (98.33% CI)P value
Mean ICA satisfaction score (1=very good to 5=very poor)
−1.1(−1.2 to −0.9)
P < 0.001
CTCA+ICA vs ICA aloneOdds ratio (98.33% CI)P value
Contrast-induced nephropathy
0.09(0.04–0.2)
P < 0.001

Secondary outcomes

OutcomeCTCA+ICAICA aloneHR (95% CI)P value
1-year MACE16.0%29.4%0.4 (0.3–0.6)P < 0.001

Safety

OutcomeCTCA+ICAICA aloneOR (95% CI)P value
Procedural complications2.3%10.8%0.2 (0.1–0.4)P < 0.001

Original publication

Computed Tomography Cardiac Angiography Before Invasive Coronary Angiography in Patients With Previous Bypass Surgery: The BYPASS-CTCA Trial. Circulation. Published 29 September 2023. doi:10.1161/circulationaha.123.064465

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.